RxDoctor Payments Data

Shopana Ganpath, MD

Internal Medicine · van Alstyne, TXNPI 1225305147

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 86 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$251
  • Currax Pharmaceuticals LLC$143
  • Pfizer$121
  • AstraZeneca$97
  • Corcept Therapeutics$88
  • Exact Sciences$77
  • plus $507 from 16 others

What the payments were for

  • Food & beverage$1,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,284 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,207
Medicare patients
257
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$62,805
XareltoRivaroxaban12$20,093
OzempicSemaglutide17$16,915
MounjaroTirzepatide12$12,269
FarxigaDapagliflozin Propanediol17$11,284
JanuviaSitagliptin Phosphate11$8,649
EliquisApixaban13$8,359
SymbicortBudesonide/Formoterol Fumarate16$5,071
Atorvastatin Calcium176$1,654
Tamsulosin Hcl53$1,147
ProgesteroneProgesterone, Micronized41$1,050
Rosuvastatin Calcium86$1,047
Gabapentin45$861
Levothyroxine Sodium104$841
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$41$62,80580 claims
Novo NordiskOzempic$53$16,91517 claims
AstraZenecaFarxiga, Symbicort$97$16,35533 claims
Lilly USA, LLCMounjaro$19$12,26912 claims
PfizerEliquis$121$8,35913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$841104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in van Alstyne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →